1. Home
  2. JFU vs IXHL Comparison

JFU vs IXHL Comparison

Compare JFU & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 9F Inc.

JFU

9F Inc.

HOLD

Current Price

$4.35

Market Cap

54.5M

Sector

Finance

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$3.25

Market Cap

97.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JFU
IXHL
Founded
2006
2001
Country
China
Australia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
97.6M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
JFU
IXHL
Price
$4.35
$3.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.6K
4.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.11
52 Week High
$9.48
$6.39

Technical Indicators

Market Signals
Indicator
JFU
IXHL
Relative Strength Index (RSI) 43.31 56.41
Support Level $4.24 $0.31
Resistance Level $5.66 $5.17
Average True Range (ATR) 0.28 0.51
MACD 0.05 0.09
Stochastic Oscillator 9.79 49.82

Price Performance

Historical Comparison
JFU
IXHL

About JFU 9F Inc.

9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: